Advanced in Pulmonary Embolism

Dr. Abhinav B. Chandra

Hematology Oncology | Hematology | Oncology
2400 S Ave A, 
Yuma, AZ 
Accepting New Patients
Offers Telehealth
Advanced in Pulmonary Embolism
2400 S Ave A, 
Yuma, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Abhinav Chandra is a Hematologist Oncology specialist and a Hematologist in Yuma, Arizona. Dr. Chandra is rated as an Advanced provider by MediFind in the treatment of Pulmonary Embolism. His top areas of expertise are Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Myelodysplastic Syndrome (MDS), and Thrombocytopenia. Dr. Chandra is currently accepting new patients.

His clinical research consists of co-authoring 42 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pulmonary Embolism.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Yuma Regional Medical Center
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

YUMA REGIONAL MEDICAL CENTER
2400 S Ave A, Yuma, AZ 85364

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Bortezomib, Lenalidomide, Dexamethasone
Study Phase: Phase 1
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy
Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy
Enrollment Status: Unknown
Publish Date: December 18, 2023
Intervention Type: Biological, Other
Study Drugs: Pertuzumab, Sargramostim, Trastuzumab, Trastuzumab Emtansine, Vaccine Therapy
Study Phase: Phase 2
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Enrollment Status: Withdrawn
Publish Date: May 26, 2022
Intervention Type: Drug, Biological
Study Drugs: Abemaciclib, Trastuzumab Emtansine
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

42 Total Publications

A Case of Solitary Amyloid Lung Nodule Treated With Surgery.
A Case of Solitary Amyloid Lung Nodule Treated With Surgery.
Journal: Cureus
Published: August 16, 2024
Similar Doctors
Experienced in Pulmonary Embolism
Dr. David G. Mayernik
Hematology Oncology | Hematology | Oncology
Experienced in Pulmonary Embolism
Dr. David G. Mayernik
Hematology Oncology | Hematology | Oncology

Yuma Regional Medical Center

2375 S Ridgeview Dr, 
Yuma, AZ 
 (1.5 miles away)
928-317-2518
Languages Spoken:
English
See accepted insurances

David Mayernik is a Hematologist Oncology specialist and a Hematologist in Yuma, Arizona. Dr. Mayernik is rated as an Advanced provider by MediFind in the treatment of Pulmonary Embolism. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Antiphospholipid Syndrome, and Lung Cancer.

Experienced in Pulmonary Embolism
Dr. Michael T. Lyster
Hematology Oncology | Hematology | Oncology
Experienced in Pulmonary Embolism
Dr. Michael T. Lyster
Hematology Oncology | Hematology | Oncology

Yuma Regional Medical Center

2375 S Ridgeview Dr, 
Yuma, AZ 
 (1.5 miles away)
928-317-2518
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Lyster is a Hematologist Oncology specialist and a Hematologist in Yuma, Arizona. Dr. Lyster is rated as an Advanced provider by MediFind in the treatment of Pulmonary Embolism. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Breast Cancer. Dr. Lyster is currently accepting new patients.

Experienced in Pulmonary Embolism
Dr. Charles A. Chacko
Hematology Oncology | Hematology | Oncology
Experienced in Pulmonary Embolism
Dr. Charles A. Chacko
Hematology Oncology | Hematology | Oncology

Yuma Regional Medical Center

2400 S Ave A, 
Yuma, AZ 
 (0.1 miles away)
928-344-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Charles Chacko is a Hematologist Oncology specialist and a Hematologist in Yuma, Arizona. Dr. Chacko is rated as an Experienced provider by MediFind in the treatment of Pulmonary Embolism. His top areas of expertise are Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), Leukocytosis, and Congenital Antithrombin 3 Deficiency. Dr. Chacko is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chandra's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 54 Advanced Conditions
    View All 116 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile